PROSION GmbH

PROSION developed a first-in-class approach to address so far undruggable pharmaceutical targets that are linked with various hard-to-treat diseases through a disruptive platform of chemical building blocks called ProMs. ProMs can in fact be combined to form the world’s first small molecule drugs for a very abundant class of “undruggables”, namely proline-rich-motif (PRM) binding targets. These targets are known to play key-roles in a multitude of pathologies, e.g. cancer, diabetes, Alzheimer’s, cardiovascular diseases, immune-meditated disorders, etc. The potential of the ProM-platform has already been validated in a first POC targeting Ena/VASP, a particularly difficult oncological PRM-binding target.